Tilray (NASDAQ:TLRY - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06), Zacks reports. The company had revenue of $185.78 million during the quarter, compared to analysts' expectations of $213.38 million. Tilray had a negative return on equity of 4.40% and a negative net margin of 30.95%. Tilray updated its FY 2025 guidance to EPS.
Tilray Trading Down 3.6 %
Shares of TLRY traded down $0.02 during mid-day trading on Friday, hitting $0.49. 22,827,649 shares of the company's stock traded hands, compared to its average volume of 29,491,812. The business's 50-day moving average price is $0.73 and its 200-day moving average price is $1.17. Tilray has a 1 year low of $0.44 and a 1 year high of $2.52. The firm has a market capitalization of $457.01 million, a P/E ratio of -1.62 and a beta of 1.88. The company has a quick ratio of 1.58, a current ratio of 2.54 and a debt-to-equity ratio of 0.10.
Analyst Upgrades and Downgrades
A number of brokerages have commented on TLRY. Canaccord Genuity Group lifted their price target on Tilray from $2.00 to $3.00 and gave the stock a "buy" rating in a research note on Monday, January 13th. Piper Sandler dropped their price target on shares of Tilray from $2.00 to $1.00 and set a "neutral" rating for the company in a research report on Wednesday.
View Our Latest Analysis on TLRY
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Featured Stories
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
